Literature DB >> 34591174

Autoimmune retinopathy: clinical, electrophysiological, and immunological features in nine patients with long-term follow-up.

Khaled Safadi1, Itay Chowers1, Eyal Banin1, Boris Rosin1, Liran Tiosano1, Radgonde Amer2.   

Abstract

PURPOSE: We aim to report on the clinical, imaging, immunological, and electrophysiological features of patients with autoimmune retinopathy (AIR) with long-term follow-up.
METHODS: Single-center, retrospective study of a consecutive group of AIR patients treated in a tertiary academic medical center.
RESULTS: Included were nine patients with a mean ± SD age at presentation of 65 ± 13 years and a median follow-up of 63 months (range 18-120). Five patients were known to have cancer. Median interval between onset of ocular symptoms and diagnosis of AIR was 36 months. Mean baseline and final LogMAR visual acuity were 0.72 ± 0.9 and 1.1 ± 1.2, respectively (p = 0.17). The most common funduscopic findings included optic atrophy and bone-spicule-like pigmentation. Thinning of the nerve fiber layer was the most frequent optical coherence tomographic abnormality. Electroretinographic (ERG) recordings demonstrated variably reduced cone- and rod-derived amplitudes in the majority of eyes at presentation. The most commonly detected anti-retinal antibody was anti-α-enolase. Treatment included immunomodulatory therapy and plasmapheresis. ERG tests showed stability in 64% of eyes throughout the treatment period.
CONCLUSION: This study highlights the importance of maintaining a high index of suspicion of AIR, particularly in late middle-aged and elderly patients with "unexplained" visual loss, in light of the non-specific posterior segment signs and the inconsistency of the routinely used ancillary tests.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Autoimmune retinopathy; Non-paraneoplastic retinopathy; Paraneoplastic retinopathy

Mesh:

Substances:

Year:  2021        PMID: 34591174     DOI: 10.1007/s00417-021-05409-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  15 in total

1.  Fluorescein angiographic findings in a case of cancer-associated retinopathy.

Authors:  N Masaoka; Y Emoto; A Sasaoka; A Fukushima; H Ueno; H Ohguro
Journal:  Retina       Date:  1999       Impact factor: 4.256

2.  Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma.

Authors:  M A Murphy; C E Thirkill; W M Hart
Journal:  J Neuroophthalmol       Date:  1997-06       Impact factor: 3.042

Review 3.  Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases.

Authors:  J Guy; N Aptsiauri
Journal:  Arch Ophthalmol       Date:  1999-04

4.  Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies.

Authors:  Richard G Weleber; Robert C Watzke; William T Shults; Karmen M Trzupek; John R Heckenlively; Robert A Egan; Grazyna Adamus
Journal:  Am J Ophthalmol       Date:  2005-05       Impact factor: 5.258

5.  Blindness caused by photoreceptor degeneration as a remote effect of cancer.

Authors:  R A Sawyer; J B Selhorst; L E Zimmerman; W F Hoyt
Journal:  Am J Ophthalmol       Date:  1976-05       Impact factor: 5.258

Review 6.  Autoimmune retinopathy.

Authors:  Landon Grange; Monica Dalal; Robert B Nussenblatt; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2013-09-29       Impact factor: 5.258

7.  A clinical triad to diagnose paraneoplastic retinopathy.

Authors:  D M Jacobson; C E Thirkill; S J Tipping
Journal:  Ann Neurol       Date:  1990-08       Impact factor: 10.422

8.  Clinical and immunologic aspects of cancer-associated retinopathy.

Authors:  Hiroshi Ohguro; Yumiko Yokoi; Ikuyo Ohguro; Kazuhisa Mamiya; Futoshi Ishikawa; Hitoshi Yamazaki; Tomomi Metoki; Yoshiko Takano; Tadashi Ito; Mitsuru Nakazawa
Journal:  Am J Ophthalmol       Date:  2004-06       Impact factor: 5.258

9.  Management of autoimmune retinopathies with immunosuppression.

Authors:  Henry A Ferreyra; Thiran Jayasundera; Naheed W Khan; Shirley He; Ying Lu; John R Heckenlively
Journal:  Arch Ophthalmol       Date:  2009-04

10.  Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy.

Authors:  Arash Maleki; Neerav Lamba; Lina Ma; Stacey Lee; Alexander Schmidt; C Stephen Foster
Journal:  Clin Ophthalmol       Date:  2017-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.